Month: September 2026

Poster presentations further characterize clinical profile of HLP003 and 
Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment
for major depressive disorder (“MDD”)

NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) — Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Three of the poster presentations build on findings from Helus Pharma’s completed Phase 1/2a randomized, double-blind study of HLP003 as a potential adjunctive therapy in participants with MDD. Data presented includes 12-month efficacy results. A trial-in-progress overview of PARADIGM, the ongoing Phase 3 clinical program of HLP003 was also presented.

Poster #1

• Title: Effects of HLP003 on MADRS Individual Items and Anhedonia Subscale in Adults With Major Depressive Disorder: Post Hoc Analysis of a Phase 1/2a Study 
• Authors: Atul R. Mahableshwarkar, MD; Ken Kramer, PhD; Alexandra Kulikova, PhD; Amir Inamdar, MBBS, DNB (Psych), MFPM
• Poster Number:124

Poster #2

• Title: Understanding and Assessing the Psychedelic Experience From a Phase 1/2a Study of the Deuterated Psilocin Analog HLP003 in Adults With Major Depressive Disorder
• Authors: Atul R. Mahableshwarkar, MD; Sunita Shinde, MD; Ken Kramer, PhD; Alexandra Kulikova, PhD; Amir Inamdar, MBBS, DNB (Psych), MFPM
• Poster Number: 123

Poster #3

• Title: Expanded Safety Analysis of the Deuterated Psilocin Analog HLP003 From a Phase 1/2a Study of Adult Participants With Major Depressive Disorder
• Authors: Sunita Shinde, MD; Alexandra Kulikova, PhD; Atul Mahableshwarkar, MD; Ken Kramer, PhD; Amir Inamdar, MBBS, DNB (Psych), MFPM
• Poster Number: 122

Poster #4

• Title: A Phase 3 Clinical Program Evaluating the Efficacy and Safety of the Deuterated Psilocin Analog HLP003 as an Adjunctive Treatment for Major Depressive Disorder (PARADIGM)
• Authors: Amir Inamdar, MBBS, DNB (Psych), MFPM; Annette Massa, PharmD; Ken Kramer, PhD; Heather Prichard, PhD; Sunita Shinde, MD; Atul Mahableshwarkar, MD
• Poster Number: 121

About Helus Pharma

Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding HLP003 as a potential adjunctive treatment for MDD; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026, and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca/ and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com

Gabriel Fahel
Chief Legal Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com

Media Contact:
Victoria Verdeja
RXMD
Public Relations Director
(212) 537-9495
vverdeja@rxmedyn.com

• This year’s theme, “Evolution Fueled by Legacy,” reminds aviation professionals that sharing the wisdom gained from past experiences can help lead to a safer, more resilient future for generations to follow
• Free-to-attend safety seminars provide lifelong learning opportunities for a wide cross-section of industry professionals
• Jam-packed lineup includes must-attend educational seminar sessions focusing on building a safety culture, reimagining team dynamics and more

MONTREAL, Sept. 21, 2026 (GLOBE NEWSWIRE) — Bombardier today announced that its highly-influential Safety Standdown safety seminar is returning to Wichita, Kansas on November 10-12, celebrating 30 years of Bombardier-led knowledge-based training in one of America’s most important aviation hubs. Bringing together aviation professionals from across America and around the world, this free-to-attend three-day seminar will be held in person and online and will feature unique learning opportunities, dynamic workshops and cutting-edge presentations by key industry thought leaders. The seminar is open to all aviation professionals from all manufacturers, regardless of the aircraft type they operate.

The theme for the milestone 30^th anniversary event focuses on “Evolution Fueled by Legacy,” reminding aviation professionals that progress doesn’t happen by chance. It happens because they choose to learn, adapt, and act. The wisdom gained from past experiences, for example, helps pave the way for our future, providing the foundation for tomorrow. Registration for this year’s milestone event is now open.

“For 30 years, Bombardier’s Safety Standdown has provided aviation professionals with invaluable opportunities to glean new perspectives on safety, helping them evolve and grow in every aspect of flight operations,” said Chris Milligan, Vice President, Pre-owned Aircraft Services and Flight Operations, Bombardier. “This free-to-attend conference is coming back to Wichita, the air capital of the world, again this year to provide aviation professionals with an opportunity to hone their skills by enabling sought-after industry experts to share invaluable information about aviation safety – and we are honoured to be safety stewards, leading the way for a better tomorrow.”

Since its inception, Safety Standdown has offered free safety-based educational opportunities for a wide range of aviation professionals. Bombardier works closely with its advisory council and key sponsors to ensure this seminar remains free of charge and explores safety knowledge-based learning in all sectors of the aviation industry.

First conceived by a group of Learjet demonstration pilots who were determined to make the Bombardier flight demonstration team in Wichita the safest in the industry, Safety Standdown continues to grow in size and scope. Attendees span the industry spectrum from flight crews and maintenance technicians to flight dispatchers and schedulers. They also represent a wide range of corporate, commercial and military organizations. Since its inception, more than 10,000 aviation professionals have attended Safety Standdown seminars worldwide, either at live seminars or through its webcasts.

Headlining this year’s seminar, as in previous years, is the popular Dr. Tony Kern, CEO of Convergent Performance. Dr. Kern will kick off this year’s event with a provocative keynote that traces a direct line from John Boyd’s legendary combat instincts to the algorithms now reshaping how we perceive risk. Other poignant presentations at this year’s milestone event include: Ivan Pupulidy, PhD, University of Alabama at Birmingham and author of “Human & Organization Potential”, exploring “Risk: The Untold Story”; Jermaine Cadogan, a 20-plus year retired U.S. Marine Corps Major who enlisted in the U.S. Marine Corps as an Aviation Ordnance Marine presenting, “Building a Culture of Excellence & Proactive Compliance”; and Tim Wade, Corporate Director of Environmental, Health & Safety, Flexjet sharing, “What you lead, you leave”, a look at the importance of sharing your safety legacy. The full program for Bombardier’s 30^th Safety Standdown can be found here.

About Bombardier

At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.

For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.

Bombardier customers operate a fleet of more than 5,200 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service centres across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico. In 2024, Bombardier was honoured with the prestigious “Red Dot: Best of the Best” award for Brands and Communication Design.

For Information

For corporate news and information, including Bombardier’s Sustainability report, as well as the company’s initiative to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book-and-Claim system visit bombardier.com.

Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.

Media Contacts
General media contact webform

Matthew Nicholls
+1-514-243-8214
Matthew.Nicholls@aero.bombardier.com

Bombardier, Learjet and Safety Standdown are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a043f5b8-5427-414d-ba6b-8f6048f0b381

VANCOUVER, British Columbia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Brutus Mining Inc. (“Brutus” or the “Company”) (CSE: BRU) announces that it proposes to undertake two concurrent non-brokered private placements for combined gross proceeds of up to approximately $3,000,000 (together, the “Offerings”): a hard dollar unit (each, a “Unit”) offering (the “Unit Offering”) and a flow-through unit (each, a “FT Unit”) offering (the “FT Offering”).

Each Unit will be sold at a price of $0.35 per Unit, for up to 5,714,285 Units and gross proceeds of up to $1,999,999.75. Each Unit will consist of one (1) common share of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.40 for a period of 24 months from the closing date.

Each FT Unit will be sold at a price of $0.40 per FT Unit, for up to 2,500,000 FT Units and gross proceeds of up to $1,000,000. Each FT Unit will consist of one (1) common share of the Company issued as a “flow-through share” within the meaning of the Income Tax Act (Canada) (a “FT Share”) and one common share purchase warrant (a “FT Warrant”). Each FT Warrant will entitle the holder to purchase one Share, which will not be a flow-through share, at a price of $0.43 for a period of 24 months from the closing date.

The Company intends to use the proceeds of the Unit Offering for exploration on the CW Property, the evaluation of new project opportunities and for general working capital purposes. The Units will be offered to qualified investors in reliance upon exemptions from the prospectus and registration requirements of applicable securities legislation. A portion of the Unit Offering may be completed in accordance with the exemption set out in BC Instrument 45–536 Exemption from prospectus requirement for certain distributions through an investment dealer and the corresponding blanket orders and rules in the other Canadian jurisdictions that have adopted the same or a similar exemption from the prospectus requirement (collectively, the “Investment Dealer Exemption“). The Investment Dealer Exemption is available in each of Alberta, British Columbia, Saskatchewan, Manitoba and New Brunswick to a person or company who has obtained advice regarding the suitability of the investment from a person registered as an investment dealer in such person’s or company’s jurisdiction. As required by the Investment Dealer Exemption, the Company confirms that, as of the date of this press release, there is no “material fact” or “material change” (as those terms are defined under applicable securities laws) related to the Company which has not been generally disclosed. The gross proceeds of the FT Offering will be used to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures” (as those terms are defined in the Income Tax Act (Canada)) (the “Qualifying Expenditures”) on the CW Property. The Company will renounce all Qualifying Expenditures to the subscribers of the FT Units with an effective date no later than December 31, 2026.

The Company will pay finders’ fees to eligible finders in connection with the Offerings, subject to compliance with applicable securities laws and the policies of the Canadian Securities Exchange. There will be a hold period of four months and one day on all securities issued under the Offerings.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Brutus Mining Inc.

Brutus Mining Inc. (CSE: BRU) is a Vancouver-based mineral exploration company. Its sole mineral property interest is an option to acquire a 100% interest in the CW Property, five contiguous mineral claims totalling 2,894.56 hectares in the Kamloops Mining Division of British Columbia, approximately 100 kilometres north of Kamloops. The Property hosts five reported MINFILE showings with copper and gold mineralization and is at an early stage of exploration. No mineral resources or mineral reserves have been estimated on the Property.

On Behalf of the Board of Directors

Christos Doulis
Chief Executive Officer, Director
+1 (604) 636-7335
info@brutusmining.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Maxus’, future growth potential for Maxus and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of copper, gold, tungsten, antimony and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Maxus’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Offerings and the intended use of proceeds therefrom; the Company’s objectives, goals or future plans; the commencement of drilling or exploration programs in the future; the completion of the Offerings. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of copper, gold, tungsten, antimony and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SANTA CLARA, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that members of its executive leadership team will participate in an Investor Breakfast Presentation during SEMICON West on Tuesday, Oct. 13, 2026. The presentation will begin at 8:00 a.m. PT and will conclude at approximately 10:30 a.m. PT.

A live webcast will be available on the Applied Materials website at: https://ir.appliedmaterials.com with a replay available the same day.

About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.

Contact:
Ricky Gradwohl (editorial/media) 408.235.4676
Mike Sullivan (financial community) 408.986.7977

“Fuel Made-in-Europe, for Europe”: Skid-mounted module readies for Portugal deployment as HyOrc targets expansion across 11 major European port hubs

HOUSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) — HyOrc Corporation (OTCQB: HYOR), an emerging clean-energy infrastructure company today announced the completion of modular off-site fabrication and assembly for its first commercial waste to methanol module. Shown below.

The modular plant is now preparing for factory testing and then transport to Portugal, establishing HyOrc’s commercial footprint in Europe.

Engineered to process approximately three tonnes-per-day of RDF—non-recyclable municipal and industrial waste—the system is designed to yield up-to one tonne-per-day of chemical-grade green methanol. By transforming domestic waste liabilities into high-value liquid fuels on European soil, HyOrc provides an industrial bridge between waste and maritime decarbonization.

Modular Skid Architecture. Our units are designed to be fully constructed and tested off-site as integrated, skid-mounted assemblies. This pre-commissioning modular approach materially reduces on-site civil works, streamlines portside integration, and minimizes installation timelines. The underlying conversion pathway—spanning gasification, syngas cleaning, conditioning, and methanol synthesis—builds upon testing witnessed and independently verified with zero non-conformities by Bureau Veritas.

Porto First. Europe’s Maritime Ports Next. The Porto deployment represents the baseline commercial blueprint for HyOrc’s modular replication strategy. Additional high-priority ports across Europe for potential locations to deploy its modular waste-to-fuel infrastructure include Algeciras, Barcelona, Genoa, Marseille, Le Havre, Antwerp, Rotterdam, Bremen, Immingham, Gdansk, Gothenburg, and Varna.

“Europe currently pays billions to manage waste while remaining reliant on imported energy commodities,” said Reginald Fubara, CEO of HyOrc Corporation. “We close that loop.”

Capital Backing and European Scale HyOrc’s Portuguese joint venture recently secured approval for a €6.7 million non-dilutive grant under the European Union STEP-Programme to support its Phase-2 expansion to 35-TPD of RDF input (~8-TPD methanol output). Additionally, HyOrc and its Bulgarian partner have applied for a €50 million EU Innovation Fund grant.

About HyOrc Corporation
HyOrc Corporation (OTCQB: HYOR) develops and commercializes patented hydrogen-capable combustion and waste-to-fuel systems for the shipping, rail, and off-grid power sectors.

Website: www.hyorc.com Press Contact: comms@hyorc.com

Forward-Looking Statements
This release contains forward-looking statements under Sections 27A and 21E of the Securities Acts of 1933 and 1934. These statements involve risks and uncertainties that may cause actual results to differ materially. Factors are described in Company filings with the SEC. The Company undertakes no obligation to update such statements.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/bcc154f0-7bb7-4e04-9894-4fb9307a68be

https://www.globenewswire.com/NewsRoom/AttachmentNg/362b3809-dd33-44be-9ad6-9cb35b6e1ba1 

https://www.globenewswire.com/NewsRoom/AttachmentNg/2479165a-be93-47e5-83ee-4edbb3442774

Integrated flood risk and property valuation solution advances recurring revenue strategy and supports expansion across markets

DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics, today announced a three-year subscription agreement with Colonnade Insurance S.A. (“Colonnade”) for an integrated flood risk and property valuation solution. Colonnade is a Luxembourg-based non-life insurance company owned by Fairfax Financial Holdings, a Canadian international financial services holding company listed on the Toronto Stock Exchange. Through its subsidiaries, Fairfax is engaged in property, liability and casualty insurance, reinsurance and investment management. The agreement advances Intermap’s strategy to scale recurring insurance analytics solutions across global markets.

The solution enables Colonnade to assess flood exposure, market value and replacement value within a single operational workflow using detailed, current and traceable property information.

“Insurance is a global growth market for Intermap, and this agreement demonstrates how our model scales,” said Patrick A. Blott, Chairman and CEO of Intermap Technologies. “Intermap is increasingly providing valuable business intelligence solutions that leverage our proprietary global geospatial data, software and expertise. We solve complex business problems by transforming geospatial information into recurring subscription solutions that can be deployed across customers, portfolios and geographies. The Colonnade deployment combines immediate operational value with a path to broader adoption, reflecting how we intend to grow our commercial insurance business worldwide.”

The agreement illustrates how Intermap applies its global geospatial intelligence and analytics to solve market-specific challenges for insurers across jurisdictions. The solution is designed to strengthen residential underwriting, portfolio review and customer-facing insurance processes while reducing the need to reconcile information from separate sources.

“Establishing an appropriate insured value is fundamental to protecting our clients,” said Marián Bátovský, CEO of Colonnade Insurance in the Czech Republic. “Combining property valuation and flood exposure in one digital workflow supports more consistent underwriting today and provides a scalable foundation as our business develops across markets.”

The subscription begins in the Czech Republic, with planned expansion into Slovakia and Hungary in 2027. Intermap and Colonnade have established an objective of extending the offering more broadly across Colonnade’s operations in Central and Eastern Europe by 2028, providing a defined path from an initial deployment to multi-country adoption.

Recent natural catastrophes, including volcanic activity in Indonesia, a major earthquake in Colombia and catastrophic flooding in Nepal, underscore the critical need for timely, location-specific risk intelligence. These events demonstrate the importance of geospatial intelligence in supporting disaster preparedness and response, guiding development and infrastructure decisions and helping governments, insurers and businesses allocate capital and resources efficiently and effectively.

Property insurers worldwide require reliable hazard intelligence and current valuation data to establish appropriate coverage, identify potential underinsurance and manage concentrations of risk across diverse portfolios. Munich Re’s NatCatSERVICE estimates that natural disasters caused approximately US$224 billion in global losses during 2025, of which insurers covered approximately US$108 billion. Intermap’s combined offering supports online market valuation of residential units, replacement value calculations for family homes and consistent property-level analysis across insurance workflows.

Swiss Re Institute reports that global insured natural catastrophe losses have increased by 5% to 7% annually in real terms over the long term, driven primarily by rising exposure and costs. Intermap’s insurance solutions combine proprietary, public and commercially available datasets with a 3D data foundation spanning more than 300 million square kilometers across more than 150 countries. This global foundation enables the Company to deliver location-specific risk intelligence for underwriting, accumulation management and portfolio monitoring through a repeatable enterprise subscription model.

Learn more about Intermap’s global insurance solutions here.

Intermap Reader Advisory

Certain information provided in this news release, including references to the planned expansion of Intermap’s Flood Risk and Property Valuation Analytics solution to additional Colonnade Insurance S.A. operations, broader adoption of the solution, the scalability of Intermap’s insurance platform, growth in recurring subscription revenue and the expansion of Intermap’s commercial insurance business globally, constitutes forward-looking statements. The words “anticipate,” “expect,” “project,” “estimate,” “forecast,” “will,” “would,” “may,” “plan,” “intend,” “grow,” “expand,” “scale” and similar expressions are intended to identify such forward-looking statements. Although Intermap believes these statements are based on information and assumptions that are current, reasonable and complete, they are necessarily subject to a variety of known and unknown risks and uncertainties. Intermap’s forward-looking statements are subject to risks and uncertainties pertaining to, among other things, customer adoption, the timing and scope of planned deployments, the Company’s ability to commercialize and scale solutions across markets, cash available to fund operations, availability of capital, revenue fluctuations, the nature of government contracts, economic conditions, loss of key customers, retention and availability of executive talent, competing technologies, common share price volatility, loss of proprietary information, software functionality, internet and system infrastructure functionality, information technology security, breakdown of strategic alliances and international and political considerations, as well as the risks and uncertainties discussed in Intermap’s Annual Information Form and other securities filings. While the Company makes these forward-looking statements in good faith, should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary significantly from those expected. Accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur or, if any of them do, what benefits the Company will derive from them. All subsequent forward-looking statements, whether written or oral, attributable to Intermap or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements contained in this news release are made as of the date of this news release. The Company does not undertake any obligation to update publicly or revise the forward-looking statements made herein, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.

About Colonnade Insurance S.A.
Colonnade Insurance S.A. is a Luxembourg-based non-life insurance company wholly owned by Fairfax Financial Holdings Limited. The company was established to support Fairfax’s strategic expansion of its insurance business in Central and Eastern Europe.

About Intermap Technologies
Intermap Technologies is a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics. The Company delivers actionable intelligence to government and commercial customers through a portfolio of applications, platforms and solutions supporting risk management, infrastructure planning, operational readiness and mission-critical decision-making. Intermap’s proprietary 3D data foundation spans more than 300 million square kilometers across more than 150 countries and powers intelligence solutions for government, insurance, aviation, telecommunications, transportation, renewable energy, agriculture, natural resources and space markets. Through advanced analytics, automated processing and enterprise-scale data delivery, Intermap helps organizations transform complex geospatial information into decision-ready intelligence.

For more information, please visit www.intermap.com or contact:
Jennifer Bakken
Executive Vice President and CFO
CFO@intermap.com
+1 (303) 708-0955

Sean Peasgood
Investor Relations
Sean@SophicCapital.com
+1 (647) 260-9266

MONTREAL, Sept. 21, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has finalized and agreed to settlement terms between Prime, Roynat Inc. (“Roynat”), and Financement Agricole Canada (“FAC” together with Roynat, the “Creditors”) and has completed a one-time cash payment of $1,010,000 to the Creditors (the “Settlement Payment”). As a result of the Settlement Payment, the Company has been released by the Creditors from all guarantees made by the Company related to loans extended to Triani Canada Inc., which represented potential exposure to the Company of up to $17.6 million.

Jean Gosselin, Chief Financial Officer of Prime, commented: “The completion of this settlement represents an important milestone for Prime. It allows us to turn the page on a significant source of uncertainty and focus our efforts fully on the next phase of our growth strategy. With the proposed acquisition of Beach Day Every Day, a premium brand that is experiencing success in Québec, together with our strategic partnership with Geloso, we are particularly well positioned to accelerate the development of BDED across the rest of Canada, the United States and Europe. We are very enthusiastic about the opportunities ahead for Prime and our shareholders.”

The completion of the Settlement Payment, together with the anticipated completion of the ongoing private placement financing as announced on August 26, 2026, will enable Prime to strengthen its balance sheet and allow the Company to better focus its resources on achieving its strategic and operational objectives.

About Prime Drink Group
Prime Drink Group Corp (CSE: PRME) is a Québec-based corporation focused on becoming a leading diversified holding company in the beverage, influencer media and hospitality sectors.

For further information, please contact:
Jean Gosselin, CFO
Phone: (514) 394-7717
Email: info@prime-group.ca

Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations (including negative and grammatical variations) of such words and phrases or statements that certain acts, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information in this press release may include, without limitation, statements relating to the completion of the private placement, and the anticipated benefits to the business of Prime due to the completion of the Settlement Payment.

These statements are based upon assumptions that are subject to significant risks and uncertainties, including risks regarding the beverage industry, market conditions, general economic factors, and the equity markets generally. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance of Prime may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although Prime believes that the expectations reflected in forward-looking statements are reasonable, they can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, Prime disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin syndrome patients and concluding further development of nodular Basal Cell Carcinoma

PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it will focus future internally sponsored clinical development of SkinJect® exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and conclude further development in sporadic/nodular basal cell carcinoma (“nBCC”).

The decision represents a further implementation of the Company’s capital-efficient portfolio strategy announced on September 8, 2026, under which Medicus is concentrating capital and organizational resources on programs where focused clinical development may offer the most compelling risk-adjusted opportunity. In that strategic update, the Company identified Gorlin syndrome, an autosomal dominant rare disease, presenting with multiple basal cell carcinoma lesions, as the strongest development opportunity for SkinJect®.

The Company has now completed a comprehensive assessment incorporating findings from an independent third-party commercial assessment commissioned by the Company, clinical input from Babar K. Rao, MD, FAAD, Clinical Associate Professor of Dermatology at Weill Cornell Medical College and Principal Investigator of the SkinJect® Phase 2 program (SKNJCT-003), findings from the final Phase 2 SkinJect® Clinical Study Report (CSR) and feedback from the U.S. Food and Drug Administration’s Office of Orphan Products Development (“OOPD”) regarding the Company’s requests for Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation (“RPDD”).

Taken together, these inputs support Medicus’s decision to concentrate SkinJect® clinical development and capital allocation exclusively on Gorlin syndrome opportunity.

Management Commentary

“Our September 8 strategic update established a clear principle for Medicus: we intend to concentrate capital where focused clinical development can create the greatest risk-adjusted value. Today’s decision applies that discipline directly to SkinJect®,” stated Dr. Raza Bokhari, Executive Chairman and CEO of Medicus. “Patients with Gorlin syndrome may face a lifetime of recurrent basal cell carcinomas and repeated procedures. We believe the FDA-authorized, NDA-enabling, Registrational SKNJCT-005 study provides us with a focused path to evaluate whether SkinJect® can offer a meaningful lesion-directed treatment option for these patients, while we continue working with the FDA to address the issues identified in our ODD and RPDD designation requests.”

FDA Feedback and Rare-Disease Strategy

In its feedback on the Company’s ODD and RPDD designation requests, the OOPD stated that it considers BCC occurring in Gorlin syndrome to be the same disease as sporadic BCC and noted that the overall prevalence of BCC exceeds the statutory prevalence threshold applicable to the designation requests. The OOPD further identified SkinJect®’s prior clinical development in BCC outside of Gorlin syndrome as relevant to its assessment of whether the program could satisfy applicable orphan-subset requirements.

The FDA has not closed either regulatory pathway. The OOPD held further review of both requests in abeyance pending receipt of additional information from the Company and provided the Company an opportunity to respond.

Medicus believes that focusing future SkinJect® clinical development exclusively on Gorlin syndrome is responsive to the issues identified by the OOPD regarding the Company’s prior development of D-MNA in BCC outside of Gorlin syndrome and provides a more coherent basis for the Company’s continued pursuit of ODD and RPDD designation. The Company intends to continue to engage with the FDA and submit additional information to the OOPD.

The OOPD also advised the Company that, irrespective of the status of the RPDD designation request, if Medicus believes SkinJect ultimately satisfies the statutory requirements for a Rare Pediatric Disease Priority Review Voucher (“PRV”), a voucher request may be included in the original marketing application together with the relevant FDA correspondence and supporting information.

If ODD is ultimately granted and applicable requirements are satisfied, potential benefits may include certain clinical-development tax incentives, exemption from certain FDA application user fees and up to seven years of U.S. orphan-drug exclusivity following approval. If SkinJect ultimately receives a qualifying approval and satisfies all statutory requirements under the RPDD program, the sponsor could potentially receive a transferable PRV.

There can be no assurance that the FDA will ultimately grant either of these designations.

FDA-Authorized, NDA-Enabling, SkinJect® Gorlin Development Program

As previously disclosed on July 27, 2026, the FDA issued a “Study May Proceed” letter to the Company authorizing the initiation of its SKNJCT-005, NDA-enabling Phase 2b study of SkinJect in patients with Gorlin syndrome, an autosomal dominant rare disease, presenting with multiple BCC lesions.

The Gorlin program builds upon the Company’s completed SKNJCT-003 Phase 2 study, which identified the 200-µg doxorubicin-loaded dissolvable microneedle array (“D-MNA”) patch as the proposed pivotal development dose.

Gorlin syndrome is characterized by the development of multiple and recurrent BCCs, which can result in substantial lifetime treatment burden from repeated surgery and other lesion-directed interventions. The Company believes SkinJect®’s localized microneedle-array delivery approach has the potential, if approved, to provide a localized lesion-directed treatment option for this population. Approximately 11,000 patients in the United States with Gorlin syndrome are estimated to have active BCC, representing approximately 50,000 Gorlin-associated BCC procedures annually.

The Gorlin-focused strategy may also potentially support a differentiated reimbursement profile. A Company-commissioned 2026 independent commercial assessment incorporating interviews with physicians and payers modeled rare-disease-anchored net pricing of approximately $25,800 per treatment, an implied U.S. total addressable market of approximately $1.1 billion, and potential peak U.S. revenue of approximately $383 million. These estimates are non-risk-adjusted and dependent upon successful clinical development, regulatory approval, reimbursement and commercial adoption.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations 
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.

The Company’s current therapeutic assets are:

CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.

SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.

Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.

Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the development of SkinJect® and the potential benefits thereof for those suffering with Gorlin Syndrome, the Company’s interpretation and characterization of the final SKNJCT-003 CSR data, the selection of the 200-mcg dose as the proposed pivotal dose, the Company’s strategy to prioritize continued clinical development of SkinJect® in Gorlin syndrome, the initiation, conduct and results of SKNJCT-005, the Company’s decision to develop SkinJect® exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and conclude further development in sporadic/nodular basal cell carcinoma, whether the FDA will grant Orphan Drug Designation or Rare Pediatric Disease designation for SkinJect® in Gorlin Syndrome and the benefits of any such designation, if granted, whether the Company will request, and ultimately qualify for, a Rare Pediatric Disease priority review voucher, the potential pricing of, and reimbursement for, SkinJect®, if approved, the estimated number of U.S. Gorlin syndrome patients with active basal cell carcinoma, the estimated annual volume of Gorlin-associated basal cell carcinoma procedures and the estimates of net price per treatment, total addressable market and potential peak U.S. revenue described in this news release, the development of Teverelix® and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix® for AURr, cardiovascular high-risk advanced prostate cancer, women’s health indications like endometriosis, the Company’s co-development with Pfizer with respect to CD228V and the anticipated benefits thereof, the Company’s plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, including the Company’s intention to focus initial development on melanoma with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, the timing, design, conduct and results of any future clinical study of CD228V, and the potential market opportunities related to CD228V, SkinJect® and Teverelix® and the Company’s other therapeutic assets. Forward-looking statements are often, but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2025, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

• Valour launches Valour Funds SPC, a new business line expanding its offering beyond exchange traded products into actively managed digital asset investment strategies.
• Smart Crypto Fund SP is its first hedge fund, providing professional and qualified investors with an actively managed strategy powered by Neuronomics’ proprietary AI strategy.
• The fund builds on Valour’s range of over 100 digital asset ETPs, more than any other digital asset manager globally, and combines Valour’s institutional infrastructure with Neuronomics’ systematic investment expertise.

TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) — DeFi Technologies Inc. (the “Company” or “DeFi Technologies”) (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B) (B3: DEFT31), a financial technology company bridging the gap between traditional capital markets and decentralized finance (“DeFi”), is pleased to announce that its subsidiary, Valour Inc., “Valour”), a leading issuer of exchange traded products (“ETPs”) has launched Valour Funds SPC (“Valour Funds”), a new business line focused on actively managed digital asset investment strategies.

Through Valour Funds, a wholly owned subsidiary of Valour Inc., the new business line is introducing Smart Crypto Fund SP, its first Hedge Fund, providing professional and qualified investors with access to an actively managed investment strategy based on artificial intelligence.

The Hedge Fund expands Valour’s investment platform beyond exchange traded products into actively managed investment solutions. It combines Valour’s institutional fund platform and digital asset infrastructure with a strategy developed and managed by Neuronomics AG, a Swiss portfolio manager specializing in artificial intelligence and systematic investing.

Smart Crypto Fund SP has been established as the first Hedge Fund portfolio of Valour Funds SPC, a Cayman Islands company registered with the Cayman Islands Monetary Authority (“CIMA”). The strategy uses proprietary AI models to adjust allocations across a regularly reviewed selection of liquid digital assets, rather than maintaining fixed exposure to a single cryptocurrency or a static basket.

“With the Smart Crypto Fund, we are expanding Valour’s investment offering beyond exchange traded products and into actively managed hedge fund strategies,” said Johan Wattenström, CEO and Chairman of DeFi Technologies. “By combining Valour’s digital asset infrastructure with Neuronomics’ AI based systematic investment expertise, we can offer professional investors an actively managed strategy within an institutional fund framework.”

AI Driven Systematic Investment Strategy

Digital asset markets offer a broad range of investment opportunities. However, they also experience significant volatility, rapidly changing conditions and substantial differences in liquidity and risk across individual assets.

The Hedge Fund is not designed to maintain a fixed allocation or remain fully exposed to the market at all times. Instead, it seeks to invest selectively when the expected balance of opportunity and risk is favorable. It also seeks to reduce exposure when model signals weaken or assessed risk increases.

Neuronomics’ proprietary AI ensemble, a group of complementary models, is central to this approach. The models analyze price, volume and other market data over short and medium time horizons. They seek to distinguish useful signals from market noise and assess potential returns, risk and market conditions.

These assessments guide the size of each position across a regularly reviewed selection of liquid digital assets. Portfolio allocations remain subject to predefined risk budgets, limits on individual assets and concentration, and controls on overall market exposure.

Trading instructions are executed using algorithms selected according to market liquidity and expected transaction costs. This disciplined process is designed to capture investment opportunities while actively managing the volatility and downside risks of digital asset markets.

“Digital asset markets generate enormous volumes of rapidly changing information, but the challenge is determining which signals matter, over what horizon and under which market conditions,” said Dr. Michael Kometer, Founder and CEO of Neuronomics AG. “Our proprietary AI ensemble helps separate signal from noise and translates forecasts into disciplined portfolio decisions. It guides what we hold, how much risk we take and when we reduce exposure.”

Institutional Infrastructure

Smart Crypto Fund SP brings together Valour’s digital asset platform, Neuronomics’ investment management capabilities and a network of specialist service providers covering fund administration, custody, banking, execution and audit.

The structure separates investment management, administration, custody and execution. This provides the operational framework required for a professionally managed digital asset investment fund.

The Launch Marks Valour’s Expansion into the Hedge Fund Segment

Valour offers over 100 digital asset ETPs, more than any other digital asset manager globally. These products give investors access to the world’s most innovative digital asset ecosystems through regulated markets.

Smart Crypto Fund complements this offering with an actively managed Hedge Fund for professional and qualified investors. The fund uses a systematic investment approach to identify opportunities across the digital asset market.

About Neuronomics AG
Neuronomics AG is a FINMA authorized Swiss portfolio manager and a pioneer in applying artificial intelligence to the professional management of digital assets. DeFi Technologies holds a minority stake in the company.

Its proprietary research combines artificial intelligence, quantitative finance and computational neuroscience to develop market forecasts. These forecasts guide portfolio allocations within disciplined risk controls. For more information, visit www.neuronomics.com.

About Valour Funds SPC
Valour Funds SPC is a Cayman Islands company and a wholly owned subsidiary of Valour Inc. The company has been established to provide professionally managed investment strategies focused on digital assets and related investment opportunities.

Smart Crypto Fund SP is the first Hedge Fund established under Valour Funds SPC.

About DeFi Technologies
DeFi Technologies Inc. (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B) (B3:DEFT31) is a financial technology company building for the convergence of traditional capital markets and decentralized finance (“DeFi”). As a publicly listed and vertically integrated digital asset platform, DeFi Technologies provides familiar, simple, secure, and regulated access to the digital asset economy through investment products, trading and liquidity infrastructure, research, and strategic capital deployment. Its business includes Valour, a leading issuer of regulated digital asset ETPs; Stillman Digital, an institutional-grade digital asset trading and liquidity platform; and DeFi Alpha, the Company’s internal business line focused on opportunistic trading, arbitrage, and other capital markets strategies. With deep expertise across capital markets and emerging technologies, DeFi Technologies is building the gateway between traditional finance and the future of digital assets. Follow DeFi Technologies on LinkedIn and X/Twitter, and for more details, visit https://defi.tech/  

DeFi Technologies Subsidiaries

About Valour
Valour Inc. and Valour Digital Securities Limited (together, “Valour”) issues exchange traded products (“ETPs”) that enable retail and institutional investors to access digital assets in a simple and secure way via their traditional bank account. Valour is part of the asset management business line of DeFi Technologies. For more information about Valour, to subscribe, or to receive updates, visit https://valour.com.

About Stillman Digital
Stillman Digital is a leading digital asset liquidity provider that offers limitless liquidity solutions for businesses, focusing on industry-leading trade execution, settlement, and technology. For more information, please visit https://www.stillmandigital.com

Cautionary note regarding forward-looking information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to proposed listing of Valour’s ETPs and DeFi Technologies’, the expected timing of listing and trading, and anticipated investor demand for digital asset ETPs; the regulatory environment with respect to the growth and adoption of decentralized finance; the pursuit by the Company and its subsidiaries of business opportunities; and the merits or potential returns of any such opportunities. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, but is not limited the acceptance of Valour exchange traded products by exchanges; growth and development of decentralised finance and digital asset sector; rules and regulations with respect to decentralised finance and digital assets; fluctuation in digital asset prices; general business, economic, competitive, political and social uncertainties. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

THE CBOE CANADA EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

For further information, please contact:

Johan Wattenstrom
Chief Executive Officer
ir@defi.tech
(323) 537-7681

HAMBURG, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) — XCHG Limited (“XCharge” or the “Company”) (Nasdaq: XCH), a global provider in high-power EV charging solutions, today informs that EnBW, operator of Germany’s largest fast-charging network, has launched the new XCharge C7 high-power charger within its nationwide fast charging network. The C7 chargers are now in operation at EnBW’s flagship charging site at its headquarters in Karlsruhe, Germany, as well as the EnBW fast charging hub in Nettetal near the Dutch border. Delivering up to 480 kW of charging power, the C7 is designed to support the next generation of electric vehicles with ever-higher charging capabilities.

XCharge C7 480 kW chargers at EnBW’s flagship charging site at its headquarters in Karlsruhe, Germany

Photo credit: EnBW / Photographer: Endre Dulic

The deployment follows the long-term partnership announced by EnBW and XCharge in February 2026. The agreement was based on a successful field test in which XCharge charging stations demonstrated their reliability, performance, and safety across tens of thousands of charging sessions.

XCharge C7 480 kW in operation at EnBW’s flagship charging site at its headquarters in Karlsruhe, Germany

Photo credit: EnBW / Photographer: Endre Dulic

Albina Iljasov, Co-CEO of XCharge, said: “With the new C7, we have introduced a product to the European market that reliably meets the demanding technical requirements of charging network operators and their customers. We are pleased that our technology will now be deployed on an ongoing basis throughout EnBW’s fast charging network, allowing us to contribute to the continued advancement of electric mobility in Germany.”

Targeted Deployment Along Long-Distance Travel Routes

“Electric mobility will continue to develop rapidly over the coming years. That’s why we’re not only expanding our fast charging network in terms of scale, but also investing specifically in new charging technology that meets both our own high standards and the expectations of our customers. With XCharge’s new 480 kW charging systems, EV drivers in the EnBW charging network benefit from short charging times, advanced technology, and high reliability,” said Lars Jacobs, CCO and Acting CTO of EnBW’s e-mobility division.

EnBW already operates more than 9,000 fast charging points across Germany and continues to expand its network in line with demand across three key segments: long-distance travel, urban areas, and retail locations. Charging infrastructure requirements vary depending on the location.

“The new 480 kW charging technology will primarily be deployed at locations where customers typically spend only a short time and want to add as much driving range as possible during their stop—for example, at EnBW fast charging parks along Germany’s major highways,” Jacobs added.

Depending on the vehicle, the new 480 kW charging technology can deliver up to 640 km of driving range in just 20 minutes. EV drivers also benefit from the higher charging capacity through dynamic power allocation when two vehicles charge simultaneously at the same station. Depending on each vehicle’s charging capabilities, this can significantly reduce charging times and maximize charging performance.

By the end of 2026, EnBW plans to bring a further double-digit number of fast charging parks equipped with XCharge’s C7 480 kW charging technology online across Germany, marking another step in the continued expansion of one of Europe’s largest fast charging networks.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “objective,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the United States Securities and Exchange Commission.

All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

About XCharge

XCharge (Nasdaq: XCH) is a global provider in high-power electric vehicle charging solutions. The Company has headquarters in Hamburg, Germany and Austin, TX, working with a globally networked team to drive innovation in the field of energy and help its customers achieve long-term success.

For investor and media inquiries, please contact:
XCHG Limited
IR Department
Email: ir@xcharge.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/0993038d-8c78-4fbe-8ccd-e0922363f68e
https://www.globenewswire.com/NewsRoom/AttachmentNg/eca903bc-6a94-4421-9305-162f104a245e